Macimorelin acetate (Ghryvelin®). HTA ID: 22062

Assessment Status Rapid Review Complete
HTA ID 22062
Drug Macimorelin acetate
Brand Ghryvelin®
Indication For the diagnosis of growth hormone deficiency (GHD) in adults.
Assessment Process
Rapid review commissioned 30/08/2022
Rapid review completed 04/10/2022
Rapid review outcome The NCPE recommends that macimorelin acetate (Ghryvelin®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement. July 2023